Saturday 17 October 2026 Export AVTX’s income statement to Excel — free account

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024. In the quarter to June 2026, revenue fell 70.1%, EPS grew 56.8% and free cash flow grew 75.7%, each against the same quarter a year earlier.

11.27 0.74 −6.16%

Follow AVTX

Alert me

Market cap: $644.1M
P/E: 0.0×
Fwd P/E: −5.2×
Dividend yield: —
F-score: 2/9
Altman Z: −2.13
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.50

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	1	4	7	2	1	5	2	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 644.10

Revenue 1.25

Net Income (100.33)

Free Cash Flow (68.29)

Net Debt (400.32)

Current Ratio 19.31

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.18)

P/S ratio 394.06

P/B ratio 1.10

Past 5Y EPS Growth —

This Y EPS Growth 50.07%

Next Y EPS Growth (2.13%)

Next Y revenue growth 280.51%

Next 5Y EPS Growth 16.97%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 96.75%

10-year low 10-year high

P/B against its own 10 years 17.56%

10-year low 10-year high

EV/Sales against its own 10 years 84.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7	135	98	400
Receivables	0	1	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	8	139	105	408

	2023	2024	2025	Q'26
Payables	0	0	0	3
ST’ Debt	—	—	—	—
Other	—	0	—	—
	5	7	13	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	(61.19%)	(85.16%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	20.30%	27.59%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0
’24	—	—	0	0	0
’23	0	1	0	1	2
’22	1	1	15	1	18
’21	0	3	1	0	5
’20	3	1	1	1	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	—	—	—
’25	(9)	(11)	(16)	(14)	(51)
’24	(6)	(16)	(12)	(15)	(49)
’23	(10)	(11)	(7)	(3)	(31)
’22	(16)	(12)	6	(4)	(27)
’21	(18)	(19)	(16)	(17)	(71)
’20	(6)	(9)	(12)	(14)	(41)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	—	—	—
’25	(9)	(82)	(16)	(14)	(51)
’24	(6)	(16)	(12)	(15)	(49)
’23	(10)	(11)	(7)	(3)	(31)
’22	(16)	(13)	6	(4)	(27)
’21	(18)	(19)	(16)	(17)	(71)
’20	(6)	(9)	(12)	(14)	(41)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.98)	(0.83)	—	—	—
’25	(1.25)	(1.92)	(2.19)	(0.37)	(5.84)
’24	(141.00)	(14.07)	(2.83)	121.45	(4.69)
’23	(202.38)	(140.48)	(26.19)	258.32	(114.00)
’22	(571.66)	(328.57)	80.95	(247.62)	(1.05k)
’21	(914.65)	(514.49)	(485.91)	(392.83)	(2.37k)
’20	(971.82)	(543.07)	(485.91)	(484.51)	(2.46k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2,183.04	979.20	6,278.40	8,380.80	4,377.60	4,608.00	581.76	7.92	3.95	3.39	Analyst estimates 2026–2028 Powerpack
	High	16,128.00	12,240.00	16,528.32	22,032.00	15,465.60	12,960.00	5,414.40	1,296.00	34.46	20.72
People
People	Employees	15	38	64	18	32	44	20	19	23	33
	Revenue/emp, $m	0.08	0.73	0.11	0.38	0.21	0.12	0.90	0.10	0.02	0.00
Income, $m
Income, $m	Revenue	1	28	7	7	7	5	18	2	0	0
	Gross margin, %	100.00	97.71	53.61	108.39	95.52	72.38	80.98	33.26	182.99	100.00
	EBT	(16)	14	(35)	(16)	(67)	(85)	(42)	(32)	(35)	(78)
	EBT margin, %	(1,428.59)	49.75	(502.58)	(236.88)	(1,002.79)	(1,566.23)	(230.62)	(1,638.77)	(7,939.91)	(132,362.71)
	Net income	(16)	12	(40)	(16)	(63)	(84)	(42)	(32)	(35)	(78)
	Depreciation	0	1	7	5	2	2	2	6	0	0
Per share, $
Per share, $	Revenue	371.94	4,345.80	576.10	450.03	287.51	154.23	460.48	6.93	0.10	0.00
	Earnings	(5,344.99)	1,200.48	(3,174.71)	(1,071.41)	(2,458.13)	(2,372.38)	(1,054.76)	(114.00)	(7.94)	(5.84)
	Cash flow	(4,701.00)	1,965.44	(256.40)	(1,275.62)	(1,739.87)	(2,025.49)	(682.42)	(110.48)	(11.08)	(3.84)
	Capex	(11.26)	(3.64)	(46.26)	(17.47)	(2.70)	(3.23)	(2.42)	0.09	0.00	0.00
	Free cash flow	(4,712.26)	1,961.80	(302.66)	(1,293.09)	(1,742.58)	(2,028.71)	(684.85)	(110.39)	(11.08)	(3.84)
	Book value	66.77	4,353.06	1,713.75	1,399.71	1,054.16	659.49	(278.44)	26.30	30.06	6.20
	Shares, m	0	0	0	0	0	0	0	0	4	13
Valuation, ×
Valuation, ×	P/E	0.00	7.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	2.21	16.15	34.49	26.44	31.75	2.61	1.26	26.37	195.21
	P/B	38.39	2.20	5.43	11.09	7.21	7.42	0.00	0.33	0.25	2.93
	EV/Sales	0.00	2.16	16.82	35.09	24.23	27.90	2.69	3.39	(72.30)	125.56
	EV/FCF	(0.40)	4.79	(32.01)	(12.21)	(4.00)	(2.12)	(1.81)	(0.21)	1.84	(1.28)
Cash, $m
Cash, $m	Operating cash flow	(15)	13	(3)	(19)	(41)	(71)	(27)	(31)	(49)	(51)
	Capex	0	0	(1)	0	0	0	0	0	—	—
	Free cash flow	(15)	13	(4)	(19)	(41)	(71)	(27)	(31)	(49)	(51)
Balance, $m
Balance, $m	Working capital	1	0	(4)	6	11	42	(6)	4	132	92
	Total debt	2	—	14	1	3	33	13	—	—	—
	Net debt	(3)	(2)	4	(10)	(16)	(22)	0	(7)	(135)	(98)
	Shareholders’ equity	0	28	21	21	25	23	(11)	7	133	83
Returns, %
Returns, %	ROA	(120.11)	32.00	(70.85)	(30.22)	(159.02)	(136.12)	(73.35)	(116.06)	(40.91)	(58.58)
	ROIC	0.00	34.20	(89.99)	(92.94)	(526.72)	(4,013.58)	0.00	0.00	0.00	0.00
	ROE	(247.87)	55.38	(164.27)	(76.72)	(278.79)	(354.20)	(684.77)	1,747.11	(50.06)	(72.43)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
AVTX Avalo Therapeutics, Inc.	$644.1M	— (loss-making)	— (loss-making)	−70.14% (below 0%: shrinking)	n/m	+75.70% (above 0%: growing)	55.73%	0.00%
WVE WAVE Life Sciences Ltd.	$628.6M	— (loss-making)	— (loss-making)	−73.88% (below 0%: shrinking)	n/m	−17.59% (below 0%: shrinking)	100.00%	(3,248.33%)	Compare
CLYM Climb Bio, Inc.	$626.6M	— (loss-making)	—	—	n/m	+3.73% (above 0%: growing)	—	0.00%	Compare
NVCT Nuvectis Pharma, Inc.	$618.0M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%	Compare
SLDB Solid Biosciences Inc.	$615.5M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−39.56% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$641.7M	—	—	−38.00%	—	−26.08%	46.21%	0.00%

All 614 Biotechnology stocks →

Avalo Therapeutics, Inc. (AVTX) key facts

Concern: Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.
Avalo Therapeutics, Inc. (AVTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AVTX traded at $11.27, a market capitalization of $644.1 million.
Return on equity was −72.4% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −2.13 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.